Dec 26 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF ROGER J. LIAS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.PEREGRINE PHARMACEUTICALS INC- LIAS SUCCEEDS STEVEN KING WHO RESIGNED AS PRESIDENT AND CEO.
Full Article
Dec 11 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.31.- COMPANY MAINTAINS ITS MANUFACTURING REVENUE GUIDANCE FOR FULL FY 2018 OF $50 MILLION - $55 MILLION.- CONSOLIDATED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS WAS $14.1 MILLION OR $0.31 PER SHARE, FOR Q2 OF FY 2018.
Full Article
Nov 28 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT.PEREGRINE PHARMACEUTICALS - CO, RONIN TRADING, SW INVESTMENT MANAGEMENT ENTERED SETTLEMENT REGARDING COMPOSITION OF PEREGRINE'S BOARD, AMONG OTHERS.PEREGRINE PHARMACEUTICALS - ON NOV 27, DIRECTORS STEVEN KING,CARLTON JOHNSON,ERIC SWARTZ & DAVID POHL TENDERED RESIGNATION IMMEDIATELY FROM BOARD.PEREGRINE PHARMACEUTICALS - VACANCIES CREATED BY THE DIRECTOR RESIGNATIONS IMMEDIATELY FILLED BY THREE INDIVIDUALS NOMINATED BY RONIN/SWIM.PEREGRINE PHARMACEUTICALS - RONIN/SWIM, WHICH COLLECTIVELY BENEFICIALLY OWNS 9.6 PERCENT OF CO, WITHDREW NOMINATION OF 6 CANDIDATES TO PEREGRINE'S BOARD.PEREGRINE PHARMACEUTICALS - RONIN/SWIM ALSO AGREED TO SOME STANDSTILL RESTRICTIONS UNTIL DATE THAT IS 30 CALENDAR DAYS AFTER 2018 ANNUAL MEETING.PEREGRINE PHARMACEUTICALS INC - PEREGRINE HAS ALSO AGREED TO RE-NOMINATE A NUMBER OF RONIN/SWIM'S APPOINTEES AT 2018 ANNUAL MEETING OF STOCKHOLDERS.
Full Article
Oct 27 (Reuters) - Peregrine Pharmaceuticals Inc ::Ronin Trading and SW Investment Management announce additional nominations to board of peregrine pharmaceuticals.ronin Trading LLC - nominating Richard B. Hancock, Joel Mccomb for election to Peregrine's board at co's 2017 annual meeting of stockholders.Ronin Trading says reiterates "demand for peregrine to hold 2017 annual meeting without further delay".Ronin Trading - co, SW Investment Management collectively own about 9.6 pct of Peregrine Pharmaceuticals Inc's outstanding shares of common stock.
Full Article
Oct 10 (Reuters) - Ronin Trading, LLC and SW Investment Management LLC::Ronin Trading and SW Investment Management announce additional nomination to Board of Peregrine Pharmaceuticals.Ronin Trading and SW Investment Management - nomination of James (Jamie) J. Egan, for election to Peregrine's Board at co's 2017 annual meeting.Ronin Trading and SW Investment Management say collectively have beneficial ownership of about 8.9% of Peregrine's outstanding shares of common stock.
Full Article
Sept 11 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine Pharmaceuticals reports financial results for first quarter of fiscal year 2018 and recent developments.Q1 loss per share $0.06.Sees Q2 2018 manufacturing revenue $50 million to $55 million.Peregrine Pharmaceuticals Inc - Most of backlog is expected to be recognized during remainder of FY 2018.Peregrine Pharmaceuticals Inc - " Avid bioservices current manufacturing revenue backlog is $33 million".Istar Inc - Company is providing manufacturing revenue guidance for full FY 2018 of $50 million - $55 million.FY2018 revenue view $56.0 million -- Thomson Reuters I/B/E/S.
Full Article
Peregrine Pharmaceuticals Inc : Qtrly total revenue $23.4 million versus $9.5 million . Peregrine Pharmaceuticals reports financial results for second quarter of fiscal year 2017 and recent developments . Q2 loss per share $0.02 .Q2 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.
Full Article
Peregrine Pharmaceuticals Inc : Peregrine pharmaceuticals reports financial results for quarter and fiscal year ended april 30, 2016 and recent developments . Q4 loss per share $0.05 . Q4 revenue $18.78 million versus i/b/e/s view $15.8 million . Q4 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S . Peregrine pharmaceuticals inc says analysis of data from sunrise phase iii trial ongoing with new clinical trials expected to commence late 2016 to early 2017 .Says Growing Biomanufacturing Demand Prompts Plans For Third Manufacturing Facility Expected To Be Commissioned By Mid 2017.
Full Article
Earnings vs. 
Estimates